C6 ceramide dramatically increases vincristine sensitivity both in vivo and in vitro, involving AMP-activated protein kinase-p53 signaling

Carcinogenesis

Volumn 36, Issue 9, 2015, Pages 1061-1070

  Chen, Min Bin ^a   Jiang, Qin ^b   Liu, Yuan yuan ^c   Zhang, Yan ^a   He, Bang shun ^d   Wei, Mu Xin ^e   Lu, Jian Wei ^f,g   Ji, Yong ^g   Lu, Pei Hua ^b,g  

^a KUNSHAN FIRST PEOPLE S HOSPITAL AFFILIATED TO JIANGSU UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c SOOCHOW UNIVERSITY   (China)

^d NANJING MEDICAL UNIVERSITY   (China)

^e THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^f JIANGSU CANCER HOSPITAL   (China)

^g WUXI PEOPLE S HOSPITAL AFFILIATED TO NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C6 CERAMIDE; CERAMIDE DERIVATIVE; CYCLOPHILIN D; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PROTEIN BCL 2; PROTEIN P53; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VINCRISTINE; CERAMIDE; CYCLOPHILIN; HIF1A PROTEIN, HUMAN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; N-(ALPHA-HYDROXYOCTADECANOYL)PHYTOSPHINGOSINE; PPID PROTEIN, HUMAN; SMALL INTERFERING RNA; TARGET OF RAPAMYCIN KINASE;

ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIZATION; DRUG SYNTHESIS; ENZYME ACTIVATION; FEMALE; GENE MUTATION; HCT116 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; MALE; MITOCHONDRION; MOUSE; NON-HODGKIN LYMPHOMA CELL LINE; NONHUMAN; OVARIAN CANCER CELL LINE; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN TRANSPORT; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; NECROSIS; NEOPLASMS; PATHOLOGY; PHYSIOLOGY; SCID MOUSE; TUMOR CELL LINE; XENOGRAFT;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; CERAMIDES; CYCLOPHILINS; DOWN-REGULATION; DRUG SYNERGISM; HCT116 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, SCID; MITOCHONDRIA; MULTIPROTEIN COMPLEXES; NECROSIS; NEOPLASM TRANSPLANTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEIN P53; VINCRISTINE;

EID: 84940660030     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgv094     Document Type: Article

References (51)

1. Morad, S.A. et al. (2013) Ceramide-orchestrated signalling in cancer cells. Nat. Rev. Cancer, 13, 51-65.
2. Lin, C.F. et al. (2006) Ceramide in apoptotic signaling and anticancer therapy. Curr. Med. Chem., 13, 1609-1616.
3. Dimanche-Boitrel, M.T. et al. (2011) Ceramide in chemotherapy of tumors. Recent Pat. Anticancer. Drug Discov., 6, 284-293.
4. Liscovitch, M. et al. (2002) Cancer multidrug resistance: a review of recent drug discovery research. IDrugs, 5, 349-355.
5. Wu, C.H. et al. (2012) Trojan-horse nanotube on-command intracellular drug delivery. Nano Lett., 12, 5475-5480.
6. Ji, C. et al. (2010) Exogenous cell-permeable C6 ceramide sensitizes multiple cancer cell lines to Doxorubicin-induced apoptosis by promoting AMPK activation and mTORC1 inhibition. Oncogene, 29, 6557-6568.
7. Zhu, Q.Y. et al. (2011) C6-ceramide synergistically potentiates the antitumor effects of histone deacetylase inhibitors via AKT dephosphorylation and α-tubulin hyperacetylation both in vitro and in vivo. Cell Death Dis., 2, e117.
8. Camplejohn, R.S. (1980) A critical review of the use of vincristine (VCR) as a tumour cell synchronizing agent in cancer therapy. Cell Tissue Kinet., 13, 327-335.
9. Chen, M.B. et al. (2011) Activation of AMP-activated protein kinase is involved in vincristine-induced cell apoptosis in B16 melanoma cell. J. Cell. Physiol., 226, 1915-1925.
10. Chen, M.B. et al. (2014) MicroRNA-451 regulates AMPK/mTORC1 signaling and fascin1 expression in HT-29 colorectal cancer. Cell. Signal., 26, 102-109.
11. Chen, M.B. et al. (2013) Activation of AMP-activated protein kinase (AMPK) mediates plumbagin-induced apoptosis and growth inhibition in cultured human colon cancer cells. Cell. Signal., 25, 1993-2002.
12. Chen, M.B. et al. (2011) Activation of AMP-activated protein kinase contributes to doxorubicin-induced cell death and apoptosis in cultured myocardial H9c2 cells. Cell Biochem. Biophys., 60, 311-322.
13. Vakana, E. et al. (2012) Targeting AMPK in the treatment of malignancies. J. Cell. Biochem., 113, 404-409.
14. Wang, S. et al. (2012) AMP-activated protein kinase, stress responses and cardiovascular diseases. Clin. Sci. (Lond)., 122, 555-573.
15. Inoki, K. et al. (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell, 115, 577-590.
16. Nieminen, A.I. et al. (2013) Myc-induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosis. Proc. Natl. Acad. Sci. USA, 110, E1839-E1848.
17. Kim, J. et al. (2011) AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol., 13, 132-141.
18. Yu, T. et al. (2013) MST1 activation by curcumin mediates JNK activation, Foxo3a nuclear translocation and apoptosis in melanoma cells. Biochem. Biophys. Res. Commun., 441, 53-58.
19. Prantner, D. et al. (2012) 5, 6-Dimethylxanthenone-4-acetic acid (DMXAA) activates stimulator of interferon gene (STING)-dependent innate immune pathways and is regulated by mitochondrial membrane potential. J. Biol. Chem., 287, 39776-39788.
20. Ji, C. et al. (2012) Ultra-violet B (UVB)-induced skin cell death occurs through a cyclophilin D intrinsic signaling pathway. Biochem. Biophys. Res. Commun., 425, 825-829.
21. Wang, B. et al. (2013) Belinostat-induced apoptosis and growth inhibition in pancreatic cancer cells involve activation of TAK1-AMPK signaling axis. Biochem. Biophys. Res. Commun., 437, 1-6.
22. Zolnik, B.S. et al. (2008) Rapid distribution of liposomal short-chain ceramide in vitro and in vivo. Drug Metab. Dispos., 36, 1709-1715.
23. Chen, M.B. et al. (2012) Perifosine sensitizes curcumin-induced anticolorectal cancer effects by targeting multiple signaling pathways both in vivo and in vitro. Int. J. Cancer, 131, 2487-2498.
24. Cao, C. et al. (2008) AMP-activated protein kinase contributes to UVand H2O2-induced apoptosis in human skin keratinocytes. J. Biol. Chem., 283, 28897-28908.
25. Jones, R.G. et al. (2005) AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell, 18, 283-293.
26. Montero, J. et al. (2013) p53 regulates a non-apoptotic death induced by ROS. Cell Death Differ., 20, 1465-1474.
27. Vaseva, A.V. et al. (2012) p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell, 149, 1536-1548.
28. Baumann, K. (2012) Cell death: multitasking p53 promotes necrosis. Nat. Rev. Mol. Cell Biol., 13, 480-481.
29. Clarke, S.J. et al. (2002) Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporin A. J. Biol. Chem., 277, 34793-34799.
30. Mihaylova, M.M. et al. (2011) The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol., 13, 1016-1023.
31. Hardie, D.G. et al. (2012) AMP-activated protein kinase: a target for drugs both ancient and modern. Chem. Biol., 19, 1222-1236.
32. Chen, M.B. et al. (2011) Activation of AMP-activated protein kinase is involved in vincristine-induced cell apoptosis in B16 melanoma cell. J. Cell. Physiol., 226, 1915-1925.
33. Kang, M.R. et al. (2012) Widdrol induces apoptosis via activation of AMP-activated protein kinase in colon cancer cells. Oncol. Rep., 27, 1407-1412.
34. Zheng, Q.Y. et al. (2012) Ursolic acid-induced AMP-activated protein kinase (AMPK) activation contributes to growth inhibition and apoptosis in human bladder cancer T24 cells. Biochem. Biophys. Res. Commun., 419, 741-747.
35. Yang, L. et al. (2015) C6 ceramide dramatically enhances docetaxelinduced growth inhibition and apoptosis in cultured breast cancer cells: a mechanism study. Exp. Cell Res., 332, 45-49.
36. Shao, J.J. et al. (2012) AMP-activated protein kinase (AMPK) activation is involved in chrysin-induced growth inhibition and apoptosis in cultured A549 lung cancer cells. Biochem. Biophys. Res. Commun., 423, 448-453.
37. Sauer, H. et al. (2012) Activation of AMP-kinase by AICAR induces apoptosis of DU-145 prostate cancer cells through generation of reactive oxygen species and activation of c-Jun N-terminal kinase. Int. J. Oncol., 40, 501-508.
38. Sun, H. et al. (2011) Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: more than just AKT inhibition. Cancer Lett., 310, 118-128.
39. Kim, Y.M. et al. (2007) Involvement of AMPK signaling cascade in capsaicin-induced apoptosis of HT-29 colon cancer cells. Ann. N. Y. Acad. Sci., 1095, 496-503.
40. Zhang, W.B. et al. (2010) Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. J. Biol. Chem., 285, 40461-40471.
41. Narbonne, P. et al. (2009) Caenorhabditis elegans dauers need LKB1/AMPK to ration lipid reserves and ensure long-term survival. Nature, 457, 210-214.
42. Jeon, S.M. et al. (2012) AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature, 485, 661-665.
43. Hardie, D.G. et al. (2012) AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol., 13, 251-262.
44. Guertin, D.A. et al. (2007) Defining the role of mTOR in cancer. Cancer Cell, 12, 9-22.
45. Brunn, G.J. et al. (1996) Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J., 15, 5256-5267.
46. Toschi, A. et al. (2008) Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2. J. Biol. Chem., 283, 34495-34499.
47. Chen, S.H. et al. (2014) Gemcitabine-induced pancreatic cancer cell death is associated with MST1/cyclophilin D mitochondrial complexation. Biochimie, 103, 71-79.
48. Chen, B. et al. (2013) Cisplatin-induced non-apoptotic death of pancreatic cancer cells requires mitochondrial cyclophilin-D-p53 signaling. Biochem. Biophys. Res. Commun., 437, 526-531.
49. Lu, J.H. et al. (2014) The mitochondrial cyclophilin D/p53 complexation mediates doxorubicin-induced non-apoptotic death of A549 lung cancer cells. Mol. Cell. Biochem., 389, 17-24.
50. Tran, M.A. et al. (2008) Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin. Cancer Res., 14, 3571-3581.
51. Stover, T.C. et al. (2005) Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin. Cancer Res., 11, 3465-3474.